Journal: Journal of Clinical Virology
, Vol. 37, Supplement I, December 2006, pg. S117. [Supplement sponsored by HHV-6 Foundation. E-Publication Jan 2007. Text can be purchased from the publisher and downloaded at http://www.sciencedirect.com/science/journal/13866532
] Authors and affiliation: J.H. Brewer. Plaza Infectious Disease and St. Luke’s Hospital, Kansas City, Missouri, USA. [E-mail: email@example.com
CFS has been associated with HHV-6 viremia in prior studies. The symptoms in CFS patients may be based on several aspects of the viral infection including a hypercoaguable syndrome [more than normal clotting].
We set out to study a potential coagulation disorder in CFS patients with previously documented HHV-6 viremia, referred to as a hypercoaguable syndrome.
30 CFS patients, in which HHV-6 viremia had been documented by rapid blood culture, were screened for a hypercoaguable syndrome utilizing a battery of tests, the ISAC (immune system activation of coagulation) panel. These patients were also screened for hereditary hypercoaguable/thrombosis risk factors using a panel of 9 hereditary tests.
80% of these patients were determined to be hypercoaguable using a criteria of two or more abnormal tests on the ISAC panel. 83% of these patients were found to have a hereditary abnormality for thrombosis risk, defined as at least one abnormal genetic test result.
A hypercoaguable syndrome is common in CFS patients. Additionally, hereditary factors are commonly seen in these patients. Active HHV-6 infection (viremia) in CFS patients may induce a hypercoaguable syndrome, which may be particularly problematic in patients who are predisposed by hereditary factors. The hypercoaguable syndrome may be involved with the symptoms of this illness.